Gerresheimer achieves all targets in 2014

Duesseldorf (ots) -

- Cross reference: Press release including table is available at
http://www.presseportal.de/dokumente -

- Revenues up 1.9% (3.7% organically) to EUR 1,290.0m
- Adjusted EBITDA totals EUR 258.5m at constant exchange rates
- Earnings per share up 6.6% to EUR 2.11
- Proposed dividend of EUR 0.75 per share
(prior year: EUR 0.70 per share)
- International expansion continues

Gerresheimer AG, one of the leading partners to the pharma and
healthcare industry worldwide, brought financial year 2014 to a
successful close. "Financial year 2014 was a good year for us. We hit
all of our targets. Demand for our packaging for the pharmaceutical
industry remained high. Since we tap into important megatrends with
our innovations and products, Gerresheimer is very well positioned
for the future," said Uwe Röhrhoff, Chief Executive Officer of
Gerresheimer AG.

Pharmaceutical packaging manufacturer Gerresheimer boosted
revenues by 1.9% to EUR 1,290.0m in financial year 2014 (December 1,
2013 to November 30, 2014). At constant exchange rates, purely
organic growth in the Company's revenues was 3.7%. Most recently,
Gerresheimer had projected organic revenue growth of around 4% for
2014. The Company achieved this increase in revenues largely with
plastic pharmaceutical packaging as well as products for the simple
and safe administration of medicines, such as insulin pens, asthma
inhalers and prefillable syringes. As expected, sales of glass
pharmaceutical primary packaging slowed somewhat, particularly due to
the weakness of the US market. Growth in the market for cosmetic
glass packaging was restrained, while sales of laboratory glassware
picked up slightly.

The Company's adjusted EBITDA came to EUR 253.4m in financial year
2014. The adjusted EBITDA of EUR 258.5m in 2014 at constant exchange
rates marginally exceeded the target corridor of EUR 255m to EUR
258m. The adjusted EBITDA margin improved from 19.1% in the prior
year to 19.5%, after deducting other operating income from a
subsidiary's put option. Net income went up by 6.4% to EUR 72.9m.
Earnings per share rose 6.6% to EUR 2.11. In 2013, this figure stood
at EUR 1.98.

Gerresheimer's capital expenditure in financial year 2014 was EUR
126.6m, representing 9.8% of revenues at constant exchange rates
(prior year: EUR 119.1m). Thereby, the Company's target for capital
expenditure in 2014, which had been 9% to 10% of revenues, has been
fully met. The Company is further expanding production capacity for
drug delivery systems such as insulin pens and asthma inhalers,